PolyActiva Pty Ltd. products

Postoperative infectious endophthalmitis is one of the most feared complications of ocular surgery.  Although rare, the complications from endophthalmitis can be catastrophic with irreversible damage to the retina and resultant visual loss. Common causative agents of bacterial endophthalmitis include Staphylococcus aureus, S. epidermidis, Pseudomonas aeruginosa and Streptococcus spp..  Consequently, the patient is instructed to use anti-inflammatory and antibiotic eye drops after surgery for up to two weeks.  While the application of anti-inflammatory and antimicrobial agents remain the gold standard of post-surgical care, the success of such therapy can be hampered by inconsistencies in patient compliance, surgical complications, and poor ocular penetration by administered agents.

Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase II.

Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery. Clinical Investigation Stage: Phase I.

For development of best-in-class ocular implants that deliver the right amount of drug, for the right period. Our technology is based on extensive scientific research leveraging our expertise in pharmaceutical, organic and polymer chemistry. The result is the creation of a unique method for precise and controlled drug delivery. Since many eye diseases are lifelong chronic disorders, a reliable and sustained delivery technology can remove the treatment burden on both patients and providers and have the potential to improve quality of life and patient outcomes.